Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of January 2024, with a filing date of January 16, 2024. The document serves as a transaction notification detailing share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). The transactions occurred on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS).
Key Financial Metrics and Transaction Details
The filing does not contain corporate financial statements, revenue, profit, or cash flow data. It exclusively reports on specific share acquisition transactions.
| Transaction Type | Instrument | Price | Volume Range | Date |
|---|---|---|---|---|
| Share Reward Plan Acquisition | Ordinary Shares | £15.7047 | 14 to 16 shares | 2024-01-10 |
| Dividend Re-investment (Share Reward Plan) | Ordinary Shares | £15.6519 | 3 to 62 shares | 2024-01-11 |
| Dividend Re-investment (ISA) | Ordinary Shares | £15.6989 | 14 to 17 shares | 2024-01-12 |
| Dividend Re-investment (ADS) | American Depositary Shares | $40.1022 | 6 to 46 shares | 2024-01-12 |
Material Changes
This filing does not report material changes to the company's financial condition, operations, or strategy. It is a routine disclosure of insider trading activity compliant with regulatory requirements.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions reported are standard acquisitions under the Company's Share Reward Plan and dividend re-investment programs.
Important Facts for Investor Verification
- Transaction Nature: All reported transactions are acquisitions, not sales, indicating no insider selling pressure during this period.
- Dividend Re-investment: Multiple executives and directors utilized dividend re-investment plans on January 11 and 12, 2024, following a dividend payment on January 11.
- Share Classes: Transactions involved both Ordinary Shares (London) and American Depositary Shares (New York), reflecting the dual-listed nature of the company.
- Participants: The filing covers a wide range of senior leadership, including the CEO (Emma Walmsley), CFO (Julie Brown), and several Independent Non-Executive Directors.